Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    Consultant-Needed-Insert
    X

    Find Drugs for Hepatology (Liver, Pancreatic, Gall Bladder) in Phase II Clinical Development in NETHERLANDS

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              NorthSea Therapeutics

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              NETHERLANDS Netherlands

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              AFSSI Connexions 2020

              Participation Not Confirmed

              Update your events

              NorthSea Therapeutics Announces US $40 Million Series B Financing to Complete Phase IIb ICONA study in NASH and to Advance Two Additional SE...

              Contact the Supplier

              Lead Product(s): Icosabutate

              Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: venBio Partners

              Deal Size: $40.0 million Upfront Cash: Undisclosed

              Deal Type: Series B Financing January 08, 2020

              Details:

              Proceeds will be used to progress the SEFA development pipeline: Completion of Ph 2b study of lead programme Icosabutate in (NASH) Initiation of clinical development of two new programmes for (PNALD)

              PharmaCompass__DigitalAd